US drug makers want greater emphasis on IP protection in India
US based drug makers lobby group Pharmaceutical Research and Manufacturers of America (PhRMA) has complained that the positive signals given by India in terms of greater intellectual property protection and market access opportunities are yet to translate into real policy actions and practical changes.
In its annual submission to the United States Trade Representative (USTR), PhRMA highlighted unpredictable patent environment, regulatory data protection failures, high tariffs and taxes on medicines, discriminatory and nobn-transparent market access policies, and unpredictable environment for clinical research as the key challenges before US companies that operate or wish to tap the Indian market.
The lobby group wants India to remain on the Priority Watch List in the 2018 Special 301 Report of USTR until India addresses their concerns.
Read more: http://bit.ly/2EHD0SK
In its annual submission to the United States Trade Representative (USTR), PhRMA highlighted unpredictable patent environment, regulatory data protection failures, high tariffs and taxes on medicines, discriminatory and nobn-transparent market access policies, and unpredictable environment for clinical research as the key challenges before US companies that operate or wish to tap the Indian market.
The lobby group wants India to remain on the Priority Watch List in the 2018 Special 301 Report of USTR until India addresses their concerns.
Read more: http://bit.ly/2EHD0SK
